2018
DOI: 10.1111/jcmm.13540
|View full text |Cite
|
Sign up to set email alerts
|

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

Abstract: Growth differentiation factor (GDF)‐15 and soluble ST2 (sST2) are established prognostic markers in acute and chronic heart failure. Assessment of these biomarkers might improve arrhythmic risk stratification of patients with non‐ischaemic, dilated cardiomyopathy (DCM) based on left ventricular ejection fraction (LVEF). We studied the prognostic value of GDF‐15 and sST2 for prediction of arrhythmic death (AD) and all‐cause mortality in patients with DCM. We prospectively enrolled 52 patients with DCM and LVEF … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
22
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 23 publications
(23 citation statements)
references
References 54 publications
0
22
0
1
Order By: Relevance
“…In a small study, sST2 was significantly higher in patients with DCM than in controls 197 . sST2 has been found to predict the risk of developing heart failure in patients with DCM in several recent studies 193,[198][199][200] . When combined with NT-proBNP, which is released under conditions of pressure overload and, therefore, is a marker for heart failure, serum sST2 levels provide additive value in predicting sudden death in patients with heart failure and an LVEF ≤45% 201 .…”
Section: Serum Biomarkersmentioning
confidence: 99%
“…In a small study, sST2 was significantly higher in patients with DCM than in controls 197 . sST2 has been found to predict the risk of developing heart failure in patients with DCM in several recent studies 193,[198][199][200] . When combined with NT-proBNP, which is released under conditions of pressure overload and, therefore, is a marker for heart failure, serum sST2 levels provide additive value in predicting sudden death in patients with heart failure and an LVEF ≤45% 201 .…”
Section: Serum Biomarkersmentioning
confidence: 99%
“…47,48 We showed previously the intracellular expression of IL-33 in human cardiac myocytes and fibroblasts, and the release of IL-33 during necrosis of these cells. 27 Moreover, the "decoy" receptor for IL-33, sST2, was shown to have predictive value in patients with coronary artery disease and HF 16,[49][50][51] as well as in critically ill patients. 52 In our study presented here, we found that fluvastatin is able to reduce secretion of sST2 from human cardiac myocytes.…”
Section: Discussionmentioning
confidence: 99%
“…Stojkovic et al demonstrated that GDF-15 is able to predict not only all-cause mortality, but also arrhythmic deaths, which are a not negligible cause of mortality in idiopathic DCM patients. GDF-15 levels above 884 pg/mL conferred a two times higher risk of arrhythmic death or resuscitated cardiac arrest and a three times higher risk of all-cause mortality, predicting the outcome with a higher accuracy than ST2 [56].…”
Section: Biomarkers and Dilated Cardiomyopathymentioning
confidence: 96%